Bristol-Myers/SciMed
Executive Summary
March 30 merger agreement has been terminated, SciMed announced, noting that the decision "was based on the fact that certain conditions relating to patents would not be satisfied." In March, an Eli Lilly subsidiary sued SciMed for patent infringement resulting from the introduction of a coronary angioplasty catheter. Company added tht the two firms "have begun discussion about the possibility of another type of relationship between them." The stock swap merger was valued at $88 mil.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.